Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures
- 7 Downloads
Purpose of Review
Pruritus in cholestatic liver disease is commonly encountered and difficult to eradicate. It has a major impact on quality of life and thus is important to address. This article reviews current and future treatment options for cholestatic pruritus.
In the last 5 years, the pathogenesis of cholestatic itch has been further clarified via studies of serum autotaxin, which correlates with severity of symptoms and decrease in patients on therapy. New medications under development include apical sodium-dependent bile acid transporters (maralixibat, GSK2330672), fibrates (bezafibrate), and κ-opioid receptor agonists (nalfurafine hydrochloride).
While many treatments are available to treat this vexing condition, data to support consistent and dramatic improvement with any one medication is lacking. However, with so many options and several new medications under investigation in clinical trials, symptom relief is an achievable goal for many patients.
KeywordsItch Primary biliary cholangitis Primary biliary cirrhosis Primary sclerosing cholangitis Bile
Compliance with Ethical Standards
Conflict of Interest
Mark Pederson declares no conflicts of interest.
Marlyn J. Mayo reports grants from Glaxo Smith Kline, Shire, Intercept, and Pfizer, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Lawley T, Yancey K. Approach to the patient with a skin disorder. In: Kasper D, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. In Fauci A BE. Harrison’s Principles of Internal Medicine USA: The McGraw-Hil Companies; 2008. p. 308–12.Google Scholar
- 3.Benito de Valle M, Rahman M, Lindkvist B, Bjornsson E, Chapman R, Kalaitzakis E. Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10(7):769–75 e2. https://doi.org/10.1016/j.cgh.2012.01.025.CrossRefPubMedGoogle Scholar
- 9.•• Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–43. https://doi.org/10.1056/NEJMoa1509840. A phase 3 study demonstrating the efficacy of obeticholic acid for the treatment of PBC experiencing suboptimal response to UDCA. CrossRefPubMedGoogle Scholar
- 10.•• Reig A, Sese P, Pares A. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol. 2018;113(1):49–55. https://doi.org/10.1038/ajg.2017.287. A trial of 48 patients demonstrating the beneficial effects of long-term bezafibrate effects in patients with PBC experiencing suboptimal response to UDCA. CrossRefPubMedGoogle Scholar
- 13.Alighieri D. Inferno. New York: Race Point Publishing; 2015.Google Scholar
- 14.Peddicord S. FDA approves Ocaliva for rare, chronic liver disease. 2016.Google Scholar
- 15.•• Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751–61 e8. https://doi.org/10.1053/j.gastro.2014.12.005. A phase 3 study demonstrating the efficacy of obeticholic acid for the treatment of PBC experiencing suboptimal response to UDCA. CrossRefPubMedGoogle Scholar
- 17.Patrick DL, Bush JW, Chen MM. Methods for measuring levels of well-being for a health status index. Helth Serv Res. 1973;8:228–45.Google Scholar
- 21.Reich A, Riepe C, Anastasiadou Z, Medrek K, Augustin M, Szepietowski JC, et al. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol. 2016;96(7):978–80. https://doi.org/10.2340/00015555-2433.CrossRefPubMedGoogle Scholar
- 26.Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neuro-Oncol. 2003;89:2441–8.Google Scholar
- 28.• Kremer AE, Feramisco J, Reeh PW, Beuers U, Receptors OERP. Cells and circuits involved in pruritus of systemic disorders. Biochim Biophys Acta. 2014;1842(7):869–92. https://doi.org/10.1016/j.bbadis.2014.02.007. An excellent review of the molecular mechanisms and neurological pathways involved in cholestatic pruritus. CrossRefPubMedGoogle Scholar
- 35.Di Padova C, Tritapepe R, Rovagnati P, Rossetti S. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol. 1984;6:773–6.PubMedGoogle Scholar
- 37.• Hegade VS, Krawczyk M, Kremer AE, Kuczka J, Gaouar F, Kuiper EM, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther. 2016;43(2):294–302. https://doi.org/10.1111/apt.13449. Evaluated the safety and effectiveness of nasobiliary drainage in 27 patients with refractory cholestatic pruritus. CrossRefPubMedGoogle Scholar
- 44.Berstein JE, Switft R. Relief of intractable pruritus with naloxone. Arch Dermatol. 1979;115:1366–7. https://doi.org/10.1001/archderm.1979.04010110058029.CrossRefGoogle Scholar
- 51.Bacq Y, le Besco M, Lecuyer AI, Gendrot C, Potin J, Andres CR, et al. Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: results in real-world conditions and factors predictive of response to treatment. Dig Liver Dis. 2017;49(1):63–9. https://doi.org/10.1016/j.dld.2016.10.006.CrossRefPubMedGoogle Scholar
- 52.• Grand’Maison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. J Obstet Gynaecol Can. 2014;36(7):632–41. https://doi.org/10.1016/s1701-2163(15)30544-2. A meta-analysis of 11 randomized controlled trials examining the safety and effectiveness of UDCA for the treatment of intrahepatic cholestasis of pregnancy. CrossRefPubMedGoogle Scholar
- 54.•• European Assocaition for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cirrhosis. J Hepatol. 2017;67:145–72. Recently updated guidelines from the European Association for the Study of the Liver on the management of PBC. CrossRefGoogle Scholar
- 56.Kuiper EM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52(4):1334–40. https://doi.org/10.1002/hep.23821.CrossRefPubMedGoogle Scholar
- 57.Hilal-Dandan R, Brunton LL. Goodman and Gilman’s manual of pharmacology and therapeutics, Second Edition. China: The McGraw-Hill Companies, Inc; 2014.Google Scholar
- 84.Oldakowska-Jedynak U, Jankowska I, Hartleb M, Jirsa M, Pawlowska J, Czubkowski P, et al. Treatment of pruritus with Prometheus dialysis and absorption system in a patient with benign recurrent intrahepatic cholestasis. Hepatol Res. 2014;44(10):E304–E8. https://doi.org/10.1111/hepr.12262. CrossRefPubMedGoogle Scholar
- 88.•• Hegade VS, Kendrick SFW, Dobbins RL, Miller SR, Thompson D, Richards D, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114–23. https://doi.org/10.1016/s0140-6736(17)30319-7. A phase 2 study of a novel ileal bile acid transporter inhibitor, GSK2330672, that demonstrated effectiveness in the treatment of cholestatic pruritus. CrossRefPubMedGoogle Scholar
- 89.•• Mayo MJ, Pockros P, Jones D, Bowlus C, Levy C, Patanwala I, et al. Clarity: a phase 2, randomized, double-blind, placebo-controlled study of lopixibat chloride (formerly Lum001), a novel apical sodium-dependent bile acid transporter inhibitor, in the treatment of primary biliary cirrhosis associated with itching. J Hepatol. 2016;64(2):S197. https://doi.org/10.1016/s0168-8278(16)00146-x. A phase 2 study of a different novel ileal bile acid transporter inhibitor, lopixibat (now maralixibat) that showed improvement in cholestatic pruritus though was not statistically significant. CrossRefGoogle Scholar
- 90.•• Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47:972–82. A phase 3 trial of a novel κ-opioid recent agonist, nalfurafine hydrochloride, demonstrating effectiveness in the treatment of cholestasis pruritus. CrossRefPubMedGoogle Scholar